DAURISMO DIN 02498480
Status: Marketed
Holder: PFIZER CANADA ULC
Health Canada record
| Active ingredient(s) | GLASDEGIB (GLASDEGIB MALEATE) 100 MG |
|---|
| Dosage form | Tablet |
|---|
| Route | Oral |
|---|
| Schedule | PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L01XJ03 GLASDEGIB |
|---|
| Original market date | 10-Aug-2020 |
|---|
| Current status date | 10-Aug-2020 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Pfizer Canada ULC — licence 100255, currently licensed, last inspection rating C (2023-08-07).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing GLASDEGIB (GLASDEGIB MALEATE)
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02498472 | DAURISMO | PFIZER CANADA ULC | Tablet | GLASDEGIB (GLASDEGIB MALEATE) 25 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 23517 | 2020-04-28 | New Drug Submission (NDS) | |
Request a quote for DAURISMO
How to read a Canadian DIN record